Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Hutchings, M. [1 ]
Sureda, A. [2 ]
Terol, M. J. [3 ]
Bosch, F. [4 ]
Corradini, P. [5 ,6 ]
Stauffer, Larsen T. [7 ]
Rueda, Dominguez A. [8 ]
Panchal, A. [9 ]
Bottos, A. [10 ]
Carlile, D.
Wang, Y. [11 ]
de L'Etang, Filezac A. [10 ]
Tandon, M.
Sellam, G. [10 ]
Gritti, G. [12 ]
机构：
[1] Rigshosp, Copenhagen, Denmark
[2] Inst Catala Oncol Hosp, Barcelona, Spain
[3] Univ Valencia, Hosp Clin Univ INCLIVA, Valencia, Spain
[4] Univ Hosp Vall Hebron, Barcelona, Spain
[5] Univ Milan, Milan, Italy
[6] Fondazione IRCCS Ist Nazl Tumori, Milan, Italy
[7] Odense Univ Hosp, Odense, Denmark
[8] Reg & Virgen Victoria Univ Hosp, Malaga, Spain
[9] Roche Prod Ltd, Welwyn Garden City, Herts, England
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] F Hoffmann Roche Ltd, Shanghai, Peoples R China
[12] Ospedale Papa Giovanni 23, Bergamo, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V195
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [1] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Hutchings, Martin
    Sureda, Anna
    Terol, Maria Jose
    Albareda, Francesc Bosch
    Corradini, Paolo
    Larsen, Thomas Stauffer
    Dominguez, Antonio Rueda
    Panchal, Anesh
    Bottos, Alessia
    Carlile, David
    Wang, Yanjie
    De L'Etang, Audrey Filezac
    Tandon, Maneesh
    Sellam, Gila
    Gritti, Giuseppe
    BLOOD, 2021, 138
  • [2] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Sehn, L. H.
    McMillan, A.
    Matasar, M. J.
    Flowers, C. R.
    Kamdar, M.
    Hertzberg, M.
    Assouline, S.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Croft, B.
    Herrera, A. F.
    Hirata, J.
    Cheng, J.
    Ku, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
  • [3] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Dietrich, S.
    Hutchings, M.
    Avigdor, A.
    Sureda, A.
    Terol, M. J.
    Bosch, F.
    Corradini, P.
    Larsen, Stauffer T.
    Dominguez, Rueda A.
    Skarbnik, A.
    Jorgensen, J.
    Goldschmidt, N.
    Gurion, R.
    Zinzani, P. L.
    Pinto, A.
    Cordoba, R.
    Bottos, A.
    Huang, Z.
    Simko, S.
    Relf, J.
    de L'Etang, Filezac A.
    Sellam, G.
    Gritti, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
  • [4] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    Assouline, Sarit
    Hertzberg, Mark
    Kim, Tae Min
    Kim, Won-Seog
    McMillan, Andrew
    Ozcan, Muhit
    Hirata, Jamie M.
    Penuel, Elicia
    Cheng, Ji
    Ku, Grace
    Flowers, Christopher R.
    BLOOD, 2018, 132
  • [5] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
  • [6] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [7] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB (POLA plus BR) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): UPDATED RESULTS OF A PHASE IB/II RANDOMIZED STUDY AND PRELIMINARY RESULTS OF A SINGLE ARM EXTENSION
    Pinto, A.
    Sehn, L. H.
    Hertzberg, M.
    Opat, S.
    Herrera, A. F.
    Assouline, S.
    Flowers, C. R.
    Kim, T. M.
    McMillan, A.
    Ozcan, M.
    Safar, V.
    Salles, G.
    Musick, L.
    Hirata, J.
    Chang, Y. M.
    Ku, G.
    Matasar, M. J.
    HAEMATOLOGICA, 2021, 106 (10) : 69 - 69
  • [8] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
    Herrera, Alex F.
    Matasar, Matthew J.
    Assouline, Sarit
    Kamdar, Manali
    Mehta, Amitkumar
    Fleury, Isabelle
    Kim, Won Seog
    Kim, Tae Min
    Bosch, Francesc
    Radford, John A.
    Bu, Lilian
    Hong, Wan-Jen
    Sehn, Laurie H.
    BLOOD, 2016, 128 (22)
  • [9] Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Shi, Yuanfei
    Xu, Yi
    Wang, Jinghan
    Zheng, Xiaolong
    Li, Xueying
    Jin, Jie
    Tong, Hongyan
    Xie, Wanzhuo
    BLOOD, 2023, 142
  • [10] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345